Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have received a $25 million grant from the National Institutes of Health (NIH) for the Harold and Muriel Block Institute for Clinical and Translational Research (ICTR) at Einstein and Montefiore. The two institutions received their initial Clinical and Translational Science Award (CTSA) from the NIH in 2008 to launch this joint collaboration.
The purpose of the CTSA program, now a component of the NIH's new National Center for Advancing Translational Sciences (NCATS), is to support scientists and clinicians in enhancing research innovation, efficiency and quality. Its goal is to accelerate the process of translating innovations into new treatments for patients and communities.
"Translation occurs at many points in the transformation of biomedical discovery to health outcomes, and teams of investigators build the most innovative research programs," said Harry Shamoon, M.D., principal investigator of the CTSA grant, professor of medicine, and associate dean for clinical and translational research at Einstein. "Supporting translational research is an inherently complex enterprise, since any one project involves multiple team members, scientific expertise and resources. Over the past five years, the Block ICTR has succeeded in launching new multidisciplinary projects and networks, and provided critical tools for investigators in cancer, pediatrics, rare diseases, infectious diseases, liver disorders, aging, diabetes and many others."
The Block ICTR was founded based on the partnership between Einstein and Montefiore and has been the centerpiece of their research relationship. As both institutions adapt to the transformations in healthcare and biomedical research in increasingly challenging times, the Block ICTR provides a home where Einstein and Montefiore's co-investments, unique strengths and natural alliances can be maximized.